The outlook of companies tied to Viagra's past presents a challenging investment landscape. While the initial boom generated substantial gains, generic copies have significantly diminished revenue. Investing in related pharmaceutical companies now requires a careful assessment of intellectual property rights , evolving medical changes, and the pros